Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

Novel cocaine analogues with promise in the treatment of cocaine addiction or overdose

Jan. 8, 1999

FDA approves OTC status for Elan's nicotine patch

Jan. 7, 1999

Selective inhibitor of neuronal dopamine transporter developed by U.S. university team

Jan. 4, 1999

Lilly develops novel 5-HT1A/5-HT1D antagonists for smoking cessation and CNS disorders

Dec. 23, 1998

SB launches smoking cessation line in European markets

Dec. 1, 1998

U.S. university researchers claim cocaine analogues for drug addiction, PD and depression

Nov. 27, 1998

Nicotinic acetylcholine receptor ligands for nicotine addiction and CNS disorders

Nov. 11, 1998

Apotex conducting early studies on oral chelating agents

Oct. 27, 1998

Animal studies provide further support for the role of dopaminergic systems in alcoholism

Oct. 26, 1998

Novel orally active iron chelator presented by Novartis researchers

Oct. 21, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Pharma industry faces long haul to get return on investment from AI
BioWorld Science
Artificial intelligence tools are springing up at multiple points along drug discovery and development, but despite the hype, as yet there is minimal return on...